HealthQuill cardiovascular diseases
Pfizer Inc. stopped its trial of danuglipron for treating chronic weight management after an asymptomatic patient developed a drug-induced liver injury that was resolved after discontinuation of the oral drug.
Uncategorized

Pfizer stops development of an investigational drug to treat obesity

HQ Team April 15, 2025: Pfizer Inc. stopped its trial of danuglipron for treating chronic weight management after an asymptomatic patient developed a.

Read More
The World Health Organization has issued new guidelines to help reform and strengthen mental health policies and systems at a time when up to 90% of the people in some nations with severe mental health conditions receive no care at all.
Health Medical Pharma

WHO unveils new guidelines to tackle mental health systems, policies

HQ Team March 26, 2025: The World Health Organization has issued new guidelines to help reform and strengthen mental health policies and systems.

Read More
The US Food and Drug Administration has greenlighted Pfizer Inc.’s respiratory syncytial virus vaccine (RSV) Abrysvo for treating lower respiratory tract disease in people 18-59 years.
Drugs Health Pharma

US drug regulator FDA approves expanded use of Pfizer’s RSV vaccine

The US Food and Drug Administration has greenlighted Pfizer Inc.’s respiratory syncytial virus vaccine (RSV) Abrysvo for treating lower respiratory tract disease in.

Read More
India’s coronary drug-eluting stent market may grow at a compound annual growth rate of 4% until 2033 on the back of a rise in coronary artery diseases, according to UK-based data analytics and consulting company, GlobalData.
Drugs Medical Pharma

Coronary drug-eluting stent market to grow 4% in India till 2033: Report

India’s coronary drug-eluting stent market may grow at a compound annual growth rate of 4% until 2033 on the back of a rise.

Read More
Eli Lilly will license manufacturing know-how of its rheumatoid arthritis baricitinib drug, branded as Olumiant, to Egypt’s EVA Pharma to expand its access to 49 nations in Africa.
Drugs Health Pharma

Eli Lilly to license rheumatoid drug-making technology to Egypt’s EVA

Eli Lilly will license manufacturing know-how of its rheumatoid arthritis baricitinib drug, branded as Olumiant, to Egypt’s EVA Pharma to expand its access to.

Read More
Molecules and microorganisms in the human body dramatically rise or fall at an average age of 44 and 60 affecting both the heart and immune functions, according to a Stanford Medicine study on the biology of ageing.
Drugs Health Pharma

Body undergoes tectonic molecular shifts at age 44, 60: Stanford Medicine

Molecules and microorganisms in the human body dramatically rise or fall at an average age of 44 and 60 affecting both the heart.

Read More
Johnson & Johnson plans to acquire Israel’s privately-held V-Wave Ltd., for an upfront payment of $600 million, according to a statement from the US-based company.
Drugs Health Pharma

J&J plans to acquire Israel’s V-Wave by paying $600 million upfront

Johnson & Johnson plans to acquire Israel’s privately-held V-Wave Ltd., for an upfront payment of $600 million, according to a statement from the.

Read More
About 400 million people globally live with alcohol and drug use disorders and of the total, 209 million people have alcohol dependence, according to a World Health Organization report.
Drugs Health Pharma

Alcohol claims 2.6 million lives yearly, 209m people are dependent: WHO

About 400 million people globally live with alcohol and drug use disorders and of the total, 209 million people have alcohol dependence, according.

Read More
The move to serve Indian millet-based food, to G20 leaders in New Delhi in September 2023 was received with surprise by many. Compared to cereals like rice and wheat, millets were not given much significance and now they are considered as super food with high nutritive value.
Drugs Health Pharma

Opinion: Feast for G20 leaders, benefits of millets exceed rice, wheat

By Dr. K. Leelamoni November 30, 2023: The move to serve Indian millet-based food, to G20 leaders in New Delhi in September 2023.

Read More
Dutch pharmaceutical company, Novo Nordisk, has stopped testing Ozempic to treat the progression of renal impairment in people with type 2 diabetes and chronic kidney disease after the interim results met certain pre-specified” criteria for efficacy.
Drugs Health Pharma

Novo Nordisk stops testing of Ozempic as kidney trial meets efficacy goals

HQ Team October 11, 2023: Dutch pharmaceutical company, Novo Nordisk, has stopped testing Ozempic to treat the progression of renal impairment in people.

Read More